Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma

Conclusion: Nivolumab is a useful and relatively safe second-line systemic therapy in patients with R/M-NPC, and even patients who do not respond to nivolumab may survive for a long time.

Source: In Vivo - August 30, 2020 Category: Research Authors: SATO, H., FUSHIMI, C., OKADA, T., MATSUKI, T., KONDO, T., OMURA, G., MIURA, K., YAMASHITA, T., OKAMOTO, I., TSUKAHARA, K. Tags: Clinical Studies Source Type: research